Johnson & Johnson $JNJ Stock: D.A. Davidson & CO. Decreases Holdings

Key Points

• D.A. Davidson reduced its Johnson & Johnson position by 2.4% in the third quarter, selling 14,772 shares and retaining 601,345 shares valued at approximately $159.2 million. Institutional investors and hedge funds own 69.55% of JNJ, while insiders sold $17.3 million worth of shares during the latest quarter.
• Johnson & Johnson reported third-quarter adjusted EPS of $2.59, beating estimates by $0.06, while revenue rose 5.9% year over year to $25.4 billion. The company declared a quarterly dividend of $1.34, or $5.36 annually, representing a 2.0% yield.
• JNJ shares opened at $273.39, near their 52-week high, and analysts maintain a consensus “Moderate Buy” rating with a $275.92 price target. However, elevated valuation, potential 2027 earnings pressure, MedTech weakness and ongoing litigation-related headlines remain key risks.

D.A. Davidson & CO. lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 601,345 shares of the company's stock after selling 14,772 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of D.A. Davidson & CO.'s portfolio, making the stock its 21st biggest position. D.A. Davidson & CO.'s holdings in Johnson & Johnson were worth $159,200,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Outlook Capital Management LLC purchased a new position in Johnson & Johnson during the second quarter worth about $28,000. Matrix Trust Co lifted its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after buying an additional 54 shares during the period. Montgomery Financial Services LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $43,000. Hanseatic Management Services Inc. acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth $52,000. Finally, Polaris Financial Partners purchased a new stake in Johnson & Johnson during the third quarter worth about $56,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 64,515 shares of company stock valued at $17,271,766. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $273.39 on Friday. The firm has a market capitalization of $658.13 billion, a PE ratio of 41.42, a P/E/G ratio of 2.70 and a beta of 0.21. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average of $265.74 and a two-hundred day moving average of $246.94. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.02.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the firm posted $2.80 EPS. The firm's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's payout ratio is presently 81.21%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Analyst Ratings Changes

A number of brokerages have recently weighed in on JNJ. Erste Group Bank cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday, October 21st. Bank of America reaffirmed a "neutral" rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Tuesday, September 29th. TD Cowen reissued a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.